who we are
Our company was founded on a bold vision: a world less dependent on antibiotics. For over a decade, our founder has pioneered immune stimulation through magnetic waves—forces we’re only beginning to understand. Like the invisible fields that guide birds across continents, these waves hold untapped power to strengthen our natural defenses.
We are aiming for a world where technology makes fighting recurrent UIT’s easier, more painless and less dependent on anti-biotics. Our solutions will be simple to use, yet relentlessly effective against infections. What began as a passion for innovation has grown into a mission. We’re proud of how far we’ve come, but we’re driven by what’s still ahead.
Our journey and where we are today
ImmunoRing R&D undergoes rigorous validation to ensure it meets the highest standards in effectiveness and safety. Our team has a several publications on its name and builds on leading publications of others. But let’s be honest: we still have obstacles to overcome. We are currently in the proces of getting METC approval for our second human clinical study for mitigating rUTI. Afterwards, we still have several steps to go, towards CE compliance. The aimed result: a device that delivers proven technical capability and clinical reliability.
-
We've demonstrated that electromagnetic fields can enhance immune function in diverse animal models.
Our comprehensive research program has revealed consistent immune-stimulating effects of low-frequency electromagnetic fields (EMFs) across multiple species and experimental models.
Our Key Discoveries
In fish and chickens, we showed that weak LF EMF exposure stimulates immune responses, providing early evidence of electromagnetic field effects on immunity (Environmentalist, 2007). Building on this, we demonstrated that EMF exposure exerts an antagonistic effect against coccidiosis infection in broiler chickens, offering potential therapeutic applications in poultry health (Poultry Science, 2007).
Our work in mammalian models further confirmed these findings: short-term ELF EMF exposure increases circulating leukocyte numbers and modulates HPA-axis signaling in mice (Bioelectromagnetics, 2016), demonstrating systemic immune activation.
The Significance
Across fish, birds, and mammals, our studies consistently show that electromagnetic fields can actively modulate immune function. This cross-species validation strengthens the scientific foundation for understanding EMF-immune system interactions.
Why It Matters
Our research opens new possibilities for EMF-based immune modulation therapies and provides critical insights into the biological mechanisms underlying electromagnetic field effects on living organisms.
-
Our Groundbreaking Study: Electromagnetic Fields Enhance Immune Defense
We've uncovered a fascinating connection between electromagnetic fields and immune function.
In our pioneering research published in the Journal of Innate Immunity (2015), we demonstrated that low-frequency electromagnetic field (LF EMF) exposure significantly boosts the immune response of human neutrophils—our body's first line of defense against infections.
Our Key Discovery
We found that neutrophils, when exposed to LF EMFs, dramatically increase production of neutrophil extracellular traps (NETs)—DNA nets coated with antimicrobial proteins that ensnare and destroy pathogens. This represents a *novel mechanism* by which electromagnetic fields can enhance immune function.
The Science Behind It
Our study identified the NADPH pathway as the critical metabolic process driving this enhancement, revealing a previously unknown interaction between electromagnetic fields and immune cell biology.
Why It Matters
This breakthrough finding suggests that electromagnetic fields can actively modulate immune function, opening new therapeutic possibilities. Our work provides the scientific foundation for developing innovative approaches that leverage this natural mechanism.
-
We've demonstrated that low-frequency electromagnetic fields can directly activate immune cells in the human body.
In our randomized, placebo-controlled crossover study published in Bioelectromagnetics (2022), we showed that exposure to a 5 μT low-frequency electromagnetic field signal for just 30 minutes activates human neutrophils in vivo.
Our Key Discovery
Using a rigorous experimental design, we measured neutrophil granularity in blood samples from healthy volunteers. Our findings confirm that LF-EMF exposure triggers a measurable activation response in these critical immune cells, providing direct evidence of electromagnetic field effects on human immunity.
The Significance
This study marks the first in vivo demonstration that low-intensity electromagnetic fields can modulate human neutrophil activity. Our work establishes a foundation for understanding how electromagnetic fields interact with the immune system in real-world conditions.
Why It Matters
This breakthrough confirms that electromagnetic fields can actively influence immune function in humans, opening new possibilities for therapeutic applications and advancing our understanding of bioelectromagnetic interactions.
-
What the study was about
A randomized controlled study investigated whether modulated extremely low-frequency electromagnetic fields (ELF-EMF) could support women suffering from chronic, antibiotic-resistant E. coli cystitis. The study included 148 women who received either ELF-EMF exposure or a placebo (sham) treatment over a four-week period.
Key discovery
The study found that women receiving ELF-EMF treatment showed significant improvements compared with the placebo group. Researchers observed a reduction in urinary E. coli levels, together with decreases in inflammatory markers such as IL-6 and improvements in reported symptoms.
The findings suggest that targeted electromagnetic field exposure may influence biological processes involved in infection response, including antimicrobial activity and immune regulation.
Why it matters
Recurrent urinary tract infections remain a major challenge, often leading to repeated antibiotic use and increasing concerns about antimicrobial resistance. This research highlights the potential of non-pharmacological approaches that support the body’s own defense mechanisms.
These findings contribute to a growing field of research exploring how low-frequency electromagnetic technology may influence immune responses, including the activity of key immune cells such as neutrophils.
ImmunoRing builds on these scientific insights by applying patented low-frequency electromagnetic technology in a practical, non-invasive, at-home solution designed to support the body’s natural response to recurrent UTIs.
-
The full study will start after METC approval. During that study, patients will get an ImmunoRing delivered at home and use it three times spread over the first days of an episode. The study will be randomized and double blind which means that for each two episodes one time the device will be active and the other time placebo. Patients and investigators will not have information what is active and what is placebo.
It is important that normal care for the episodes continues unchanged, including how it is decided to use antibiotics and when. In that way true and objective evidence can be gathered on whether and how ImmunoRing reduces pain, helps resolve the infection quickly, and reduce how often antibiotics are needed.
-
Planned to achieve after human pilot study to have a safe and effective ImmunoRing.
the team
Jan cuppen PhD. - founder
With a 20 year career at Philips Medical Systems in RT, MRI and CT systems, Jan is a specialist on designing and scaling medical devices. Because of his 10 years groundbreaking research work in ImmunoRing, he has become an expert on the effect of electromagnetic fields on Immune system activation.
Reon smits - CTO
With over 10 years of designing and developing MedTech and AI devices at MenTech and TrueVision, Reon leads ImmunoRing’s technical architecture.
Joost van de Velde - CEO
With over 20 years of leading a specialized marketing and innovation agency, Joost has worked for a wide range of leading MedTech and pharmaceutical brands like Omron Healthcare, Viatris, Pfizer, Merck and Roche. Joost leads ImmunoRing’s global growth. He has worked out of Mexico, San Fransisco and Eindhoven.
medical Advisory Board
Prof. Dr. Huub Savelkoul - Immunologist, Professor Emeritus Wageningen University
Specialist in cellular and molecular immunology, with a focus on immune regulation, allergies, and the development of immunological therapies and diagnostics.
Dr. Dick Janssen - urologist, Radboud UMC, Andros Blaascentrum
Urologist specialising in bladder function and problems. Principal investigator in ongoing bladder resistence improvement treatments.
help us launch immunoring
We’re modernizing the way rUTIs are treated. Less anti biotics, less pain, less hassle. In order to do so, we’d love to get in touch with you. On a weekly basis, we have group calls or individual calls with our community members, to get to know their experiences with rUTIs, validate our product design and to invite you to our latest clinical trials. Whether you are a patient, healthcare professional and investor, we’d love to have you in our community.
